FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Serum insulin concentrations in horses with equine Cushing&#...
Equine veterinary journal2004; 36(3); 295-298; doi: 10.2746/0425164044877288

Serum insulin concentrations in horses with equine Cushing’s syndrome: response to a cortisol inhibitor and prognostic value.

Abstract: Serum insulin concentration and its use as a prognostic indicator in horses with equine Cushing's syndrome (ECS) have been poorly documented. Objective: To examine daily insulin variations in horses with ECS and the effect of treatment using trilostane, a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase. Further, we aimed to examine the relationship between baseline serum insulin concentration and survival in horses with ECS. Methods: Basal serum insulin concentrations were measured in 20 confirmed ECS cases by taking blood at regular 4 h intervals for 24 h (1200, 1600, 2000, 2400, 0400 and 0800 h) before treatment (Day 0) and 10 days, and 30 days and 1-2 years after the onset of trilostane therapy. The temporal pattern of insulin was analysed using a linear mixed model approach, and the prognostic value of measurements on Day 0 assessed using receiver-operating characteristic analysis. Results: Horses with ECS showed a diurnal pattern of serum insulin concentration, highest value at 1200 h, and this pattern was not altered by treatment with trilostane. Furthermore, despite a mild increase of serum insulin concentrations after 10 days of trilostane therapy, insulin concentration was unaffected in the long-term. Low serum insulin concentrations at the beginning of the trial were significantly associated with improved survival to 1-2 years. The 1200 h sampling before treatment had the highest prognostic value for prediction of survival with a sensitivity and specificity of at least 90% for serum insulin at 188 microu/ml to predict survival and nonsurvival, respectively. Conclusions: Insulin is a useful prognostic indicator for ECS, but potentially large variations can occur throughout a 24 h period, indicating a single sample may not be representative. Serum insulin concentration did not increase over 1-2 years in horses receiving trilostane therapy.
Get Full Text
Publication Date: 2004-05-19 PubMed ID: 15147141DOI: 10.2746/0425164044877288Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses the relation between serum insulin concentrations in horses diagnosed with equine Cushing’s syndrome (ECS) and the impact of treatment using trilostane, a cortisol inhibitor. The study also evaluates the prognostic value of serum insulin levels, signifying the potential to predict the survival rates of the animals afflicted with ECS.

Objective and Methodology

  • The study aimed to investigate daily variations in insulin levels in horses affected by ECS and the possible effects of trilostane treatment on these levels.
  • The researchers also aimed to scrutinize the correlation between baseline serum insulin concentration and survival rates in horses suffering from ECS.
  • The study involved 20 diagnosed ECS cases and blood samples were taken every 4 hours over a 24 hour period before treatment, as well as at various intervals post treatment commencement.
  • A linear mixed-model approach was used for analyzing the temporal pattern of insulin, and the prognostic value of measurements on Day 0 were examined using receiver-operating characteristic analysis.

Findings

  • The study revealed that horses with ECS demonstrated a diurnal pattern of serum insulin concentration, with the highest value noted at 1200 h. This pattern remained unchanged despite trilostane treatment.
  • The serum insulin concentration showed a mild increase after 10 days of trilostane therapy but remained stable over the long-term.
  • Lower serum insulin concentrations at the onset of the trial were significantly linked to improved survival rates over a 1-2 year period.
  • Interestingly, the 1200 h sampling before treatment demonstrated the highest prognostic value for predicting survival, with a sensitivity and specificity of at least 90% for serum insulin levels at 188 microu/ml to predict survival and non-survival, respectively.

Conclusions

  • The examination concluded that insulin proves to be a functional prognostic indicator for ECS, although potential large variations can occur during a 24 h period, indicating that a single sample may not always be representative.
  • Additionally, it was established that the serum insulin concentration did not significantly rise over a 1-2 year period in horses undergoing trilostane therapy.

Cite This Article

APA
McGowan CM, Frost R, Pfeiffer DU, Neiger R. (2004). Serum insulin concentrations in horses with equine Cushing’s syndrome: response to a cortisol inhibitor and prognostic value. Equine Vet J, 36(3), 295-298. https://doi.org/10.2746/0425164044877288

Publication

Equine veterinary journal
ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 36
Issue: 3
Pages: 295-298

Researcher Affiliations

McGowan, C M
  • Department of Veterinary Clinical Sciences, The Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire AL9 7TA, UK.
Frost, R
    Pfeiffer, D U
      Neiger, R

        MeSH Terms

        • 3-Hydroxysteroid Dehydrogenases / metabolism
        • Animals
        • Biomarkers / blood
        • Cushing Syndrome / blood
        • Cushing Syndrome / drug therapy
        • Cushing Syndrome / veterinary
        • Dihydrotestosterone / analogs & derivatives
        • Dihydrotestosterone / therapeutic use
        • Enzyme Inhibitors / therapeutic use
        • Horse Diseases / blood
        • Horse Diseases / drug therapy
        • Horses
        • Hydrocortisone / antagonists & inhibitors
        • Hydrocortisone / blood
        • Insulin / blood
        • Predictive Value of Tests
        • Prognosis
        • Sensitivity and Specificity
        • Survival Analysis

        Citations

        This article has been cited 17 times.
        1. Stefaniuk-Szmukier M, Piórkowska K, Ropka-Molik K. Equine Metabolic Syndrome: A Complex Disease Influenced by Multifactorial Genetic Factors. Genes (Basel) 2023 Jul 27;14(8).
          doi: 10.3390/genes14081544pubmed: 37628596google scholar: lookup
        2. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary Pars Intermedia Dysfunction (PPID) in Horses. Vet Sci 2022 Oct 10;9(10).
          doi: 10.3390/vetsci9100556pubmed: 36288169google scholar: lookup
        3. Sillence M, Meier A, de Laat M, Klee R, Reiche D. Demographic, morphologic, hormonal and metabolic factors associated with the rate of improvement from equine hyperinsulinaemia-associated laminitis. BMC Vet Res 2022 Jan 18;18(1):49.
          doi: 10.1186/s12917-022-03149-zpubmed: 35042535google scholar: lookup
        4. Hicks GR, Fraser NS, Bertin FR. Changes Associated with the Peri-Ovulatory Period, Age and Pregnancy in ACTH, Cortisol, Glucose and Insulin Concentrations in Mares. Animals (Basel) 2021 Mar 20;11(3).
          doi: 10.3390/ani11030891pubmed: 33804751google scholar: lookup
        5. Horn R, Stewart AJ, Jackson KV, Dryburgh EL, Medina-Torres CE, Bertin FR. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses. J Vet Intern Med 2021 Jan;35(1):560-570.
          doi: 10.1111/jvim.16017pubmed: 33368633google scholar: lookup
        6. Hodge E, Kowalski A, Torcivia C, Lindborg S, Stefanovski D, Hart K, Frank N, van Eps A. Effect of thyrotropin-releasing hormone stimulation testing on the oral sugar test in horses when performed as a combined protocol. J Vet Intern Med 2019 Sep;33(5):2272-2279.
          doi: 10.1111/jvim.15601pubmed: 31432575google scholar: lookup
        7. de Laat MA, Reiche DB, Sillence MN, McGree JM. Incidence and risk factors for recurrence of endocrinopathic laminitis in horses. J Vet Intern Med 2019 May;33(3):1473-1482.
          doi: 10.1111/jvim.15497pubmed: 30972832google scholar: lookup
        8. Durham AE, Frank N, McGowan CM, Menzies-Gow NJ, Roelfsema E, Vervuert I, Feige K, Fey K. ECEIM consensus statement on equine metabolic syndrome. J Vet Intern Med 2019 Mar;33(2):335-349.
          doi: 10.1111/jvim.15423pubmed: 30724412google scholar: lookup
        9. de Laat MA, Sillence MN, Reiche DB. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis. J Vet Intern Med 2019 May;33(3):1456-1463.
          doi: 10.1111/jvim.15419pubmed: 30697823google scholar: lookup
        10. Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One 2018;13(9):e0203655.
          doi: 10.1371/journal.pone.0203655pubmed: 30212530google scholar: lookup
        11. Bertin FR, Ruffin-Taylor D, Stewart AJ. Insulin dysregulation in horses with systemic inflammatory response syndrome. J Vet Intern Med 2018 Jul;32(4):1420-1427.
          doi: 10.1111/jvim.15138pubmed: 29749643google scholar: lookup
        12. Morgan RA, Keen JA, Walker BR, Hadoke PW. Vascular Dysfunction in Horses with Endocrinopathic Laminitis. PLoS One 2016;11(9):e0163815.
          doi: 10.1371/journal.pone.0163815pubmed: 27684374google scholar: lookup
        13. de Laat MA, Hampson BA, Sillence MN, Pollitt CC. Sustained, Low-Intensity Exercise Achieved by a Dynamic Feeding System Decreases Body Fat in Ponies. J Vet Intern Med 2016 Sep;30(5):1732-1738.
          doi: 10.1111/jvim.14577pubmed: 27639952google scholar: lookup
        14. Johnson PJ, Wiedmeyer CE, LaCarrubba A, Ganjam VK, Messer NT 4th. Diabetes, insulin resistance, and metabolic syndrome in horses. J Diabetes Sci Technol 2012 May 1;6(3):534-40.
          doi: 10.1177/193229681200600307pubmed: 22768883google scholar: lookup
        15. Johnson PJ, Wiedmeyer CE, Messer NT, Ganjam VK. Medical implications of obesity in horses--lessons for human obesity. J Diabetes Sci Technol 2009 Jan;3(1):163-74.
          doi: 10.1177/193229680900300119pubmed: 20046661google scholar: lookup
        16. Menzies-Gow NJ. Equine Pituitary Pars Intermedia Dysfunction. Vet Sci 2025 Aug 20;12(8).
          doi: 10.3390/vetsci12080780pubmed: 40872730google scholar: lookup
        17. Galinelli NC, Bamford NJ, Erdody ML, Mackenzie SA, Warnken T, Harris PA, Sillence MN, Bailey SR. Effect of pergolide treatment on insulin dysregulation in horses and ponies with pituitary pars intermedia dysfunction. Equine Vet J 2025 Nov;57(6):1612-1622.
          doi: 10.1111/evj.14468pubmed: 39967360google scholar: lookup
        Subscribe to our newsletter
        Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.